Cosentyx unoready 300 MG pen 2ML
Ended Awarded
- Contract number
- SPE2DB25FKPMA
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $27,701
Award facts
- Contract value 100% obligated
- $27,700.97 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency (DLA) awarded a delivery order valued at $27,700.97 to AmerisourceBergen Drug Corp for the supply of Cosentyx (secukinumab) 300 mg pen injections in 2 mL formulations. This is a firm fixed price delivery order with no set-aside designation, competitively awarded under AmerisourceBergen's existing indefinite delivery contract (IDC) with DLA Troop Support Medical. The contract is expected to be completed by September 15, 2025, with fulfillment occurring at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Cosentyx is a biologic immunosuppressant used primarily for treating autoimmune conditions including psoriasis, psoriatic arthritis, and ankylosing spondylitis, indicating this procurement supports military and defense healthcare requirements.
AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement through the DLA Medical Supply Chain. This delivery order is issued under the company's comprehensive IDC with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This prime contract vehicle enables AmerisourceBergen to supply an extensive range of pharmaceutical products and medical supplies to support military healthcare programs globally, serving customers including the Defense Health Agency and the U.S. Coast Guard. The DLA's pharmaceutical procurement strategy involves multiple prime vendors to ensure adequate supply chain capacity and redundancy across regional therapeutic and medical supply requirements.
Quick answers
Who was awarded contract SPE2DB25FKPMA?
SPE2DB25FKPMA was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on September 12, 2025.
How much is contract SPE2DB25FKPMA worth?
The government has obligated $27,701 on SPE2DB25FKPMA.
Is contract SPE2DB25FKPMA an order under another contract?
Yes. SPE2DB25FKPMA is a delivery order under SPE2DB24D2101, an indefinite delivery contract.
Was contract SPE2DB25FKPMA competed?
The extent of competition for SPE2DB25FKPMA was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award